研究单位：[1]BeiGene[2]Peking Union Medical College Hospital [3]Peking University People's Hospital[4]Tongji Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology
研究目的：
This was a single-arm, multicenter Phase 2 study in Chinese participants with relapsed or refractory Waldenström's macroglobulinemia who exhibited one or more of the criteria for requiring treatment based on consensus guidelines from the Seventh International Workshop on Waldenström's Macroglobulinemia (IWWM). The study comprised an initial screening phase (up to 28 days), a single-arm treatment phase, and a follow-up phase.
